Dr. David A. Morrow, MD
Cardiology (Cardiovascular Disease Physician)
- Medicare participating
At a glance
- Medical school
- Harvard Medical School (1994)
- Years since graduation
- 32
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,054
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1994Medical school: Harvard Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
MA license 152630
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Brigham and Women's Hospital Boston, MA
- Newton-Wellesley Hospital Newton, MA
- Brigham and Women Faulkner Hospital Jamaica Plain, MA
- South Shore Hospital South Weymouth, MA
Medical groups
- Brigham and Womens Physicians Organization Inc (2,994 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,054
- Services billed
- 1,502
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 1,037 | 862 |
| Critical care, first 30-74 minutes | 145 | 54 |
| Established patient office or other outpatient visit, 30-39 minutes | 37 | 36 |
| Established patient office or other outpatient visit, 20-29 minutes | 31 | 29 |
| Established patient office or other outpatient visit, 40-54 minutes | 30 | 29 |
| Critical care, each additional 30 minutes | 24 | 13 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 22 | 19 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 19 | 13 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Atorvastatin Calcium Other prescribers in Boston, MA | 202 |
| Metoprolol Succinate Other prescribers in Boston, MA | 93 |
| Ezetimibe Other prescribers in Boston, MA | 77 |
| Jardiance (empagliflozin) Other prescribers in Boston, MA | 56 |
| Rosuvastatin Calcium Other prescribers in Boston, MA | 51 |
| Lisinopril Other prescribers in Boston, MA | 47 |
| Furosemide Other prescribers in Boston, MA | 44 |
| Eliquis (apixaban) Other prescribers in Boston, MA | 42 |
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Boston, MA | 29 |
| Entresto (sacubitril/valsartan) Other prescribers in Boston, MA | 24 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $2,717 in total to this clinician.
| Novartis Pharmaceuticals Corporation | $2,700 |
|---|---|
| Angiodynamics, Inc. | $17.39 |
| Consulting Fee | $2,700 |
|---|---|
| Food and Beverage | $17.39 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation Dec 8, 2025 | Consulting Fee LEQVIO · Cardiology/Vascular Diseases | $2,700 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 3 industry-funded studies in 2025, from 3 companies. The companies reported $1,163,773 in research payments for these studies, mostly to the institutions running them.
- A phase 2 doubleblind randomized placebocontrolled 4ARM study to investigate symptoms function healthrelated quality of life and safety with repeated subcutaneous administration of ponsegromab versus placebo in adult …
Pfizer Inc. - A Phase IIB Randomized Double blinded Placebo controlled Parallel group Study to Evaluate the Efficacy and Safety of MEDI6570 in Participants with a Prior Myocardial Infarction Persistent Inflammation and Elevated N t…
AstraZeneca UK Limited - Observational Assessment of Support With Impella Best Practices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
Abiomed
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.